… Not a single NRAS- or TET2-mutated patient belonging to the adverse-risk group was disease-…
Likewise, the outcome of 131 patients in the new intermediate-risk group also improved in …

… Outcome in patients with acute myeloid leukemia (AML) ranges … -treatment mutation status
of various genes has improved our … ARCH7 (ie, mutations in DNMT3a, TET2, and ASXL1) and …

… to ELN classification and the existence of signaling mutation. … 42, 43 the 2017 European
LeukemiaNet AML guidelines 30 … found MA decreased relapse risk and improved survival and …

… The European Leukemia Net 2022 risk classification … , could be improving with the FDA
approval of 11 new drugs or … similar to those observed when TET2 is mutated. The IDH1 and …

… Four patients were reclassified from intermediate to adverse risk due to mutations in
myelodysplastic related genes (U2AF1 and SRSF2). Therefore, we observed an increase in patients …

… updated by the European LeukemiaNet. Treatment options … newly diagnosed acute myeloid
leukaemia, leading to improved … with CEBPA mutation, where the definition of acute myeloid …

… TET2 mutation based on ELN risk stratification We evaluated the prognosis of TET2
mutation based on ELN risk stratification… don’t develop AML. Many researchers proposed a …

… European LeukemiaNet 2022 risk classification by genetics at initial diagnosis of acute
myeloid … With an increase in the number of mutations per AML genome obtained through …

… FLT3-ITD and mutations in WT1, DMNMT3, and TET2 were prevalent in the intermediate …
of midostaurin and chemotherapy improved OS in FLT3-mutated patients (Supplementary …

… a significant OS improvement with azacitidine vs CCR for patients with European LeukemiaNet-…
small number of azacitidine-treated patients with TET2 mutations in this analysis (n = 22) …